X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs DIVIS LABORATORIES - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA DIVIS LABORATORIES GLENMARK PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 14.1 18.5 76.1% View Chart
P/BV x 3.9 4.0 98.6% View Chart
Dividend Yield % 0.3 1.5 20.8%  

Financials

 GLENMARK PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-16
DIVIS LABORATORIES
Mar-16
GLENMARK PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,2622,484 50.8%   
Low Rs672918 73.1%   
Sales per share (Unadj.) Rs270.6142.3 190.2%  
Earnings per share (Unadj.) Rs24.941.9 59.4%  
Cash flow per share (Unadj.) Rs34.446.3 74.3%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.20.6 35.2%  
Book value per share (Unadj.) Rs151.3161.5 93.7%  
Shares outstanding (eoy) m282.16265.47 106.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.612.0 29.9%   
Avg P/E ratio x38.940.6 95.7%  
P/CF ratio (eoy) x28.136.7 76.5%  
Price / Book Value ratio x6.410.5 60.7%  
Dividend payout %8.023.9 33.7%   
Avg Mkt Cap Rs m272,778451,525 60.4%   
No. of employees `00010.03.7 270.4%   
Total wages/salary Rs m13,7823,649 377.7%   
Avg. sales/employee Rs Th7,614.910,184.4 74.8%   
Avg. wages/employee Rs Th1,374.8984.1 139.7%   
Avg. net profit/employee Rs Th700.22,998.5 23.4%   
INCOME DATA
Net Sales Rs m76,34037,764 202.2%  
Other income Rs m356848 42.0%   
Total revenues Rs m76,69638,612 198.6%   
Gross profit Rs m14,17214,138 100.2%  
Depreciation Rs m2,6911,182 227.7%   
Interest Rs m1,78923 7,710.8%   
Profit before tax Rs m10,04813,781 72.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,0282,662 113.7%   
Profit after tax Rs m7,01911,119 63.1%  
Gross profit margin %18.637.4 49.6%  
Effective tax rate %30.119.3 156.0%   
Net profit margin %9.229.4 31.2%  
BALANCE SHEET DATA
Current assets Rs m59,09630,947 191.0%   
Current liabilities Rs m40,0185,195 770.3%   
Net working cap to sales %25.068.2 36.6%  
Current ratio x1.56.0 24.8%  
Inventory Days Days75117 64.2%  
Debtors Days Days11985 140.0%  
Net fixed assets Rs m39,07517,027 229.5%   
Share capital Rs m282531 53.2%   
"Free" reserves Rs m30,28142,341 71.5%   
Net worth Rs m42,70342,877 99.6%   
Long term debt Rs m24,8735 529,212.8%   
Total assets Rs m111,02649,684 223.5%  
Interest coverage x6.6595.0 1.1%   
Debt to equity ratio x0.60 531,375.3%  
Sales to assets ratio x0.70.8 90.5%   
Return on assets %7.922.4 35.4%  
Return on equity %16.425.9 63.4%  
Return on capital %17.532.2 54.4%  
Exports to sales %43.385.3 50.8%   
Imports to sales %7.422.9 32.4%   
Exports (fob) Rs m33,04432,198 102.6%   
Imports (cif) Rs m5,6728,654 65.5%   
Fx inflow Rs m36,94532,270 114.5%   
Fx outflow Rs m61,0668,775 695.9%   
Net fx Rs m-24,12223,496 -102.7%   
CASH FLOW
From Operations Rs m3,44910,379 33.2%  
From Investments Rs m-8,802-4,135 212.9%  
From Financial Activity Rs m6,986-6,241 -111.9%  
Net Cashflow Rs m9343 28,297.0%  

Share Holding

Indian Promoters % 48.3 52.0 92.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 11.8 58.5%  
FIIs % 34.4 19.0 181.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.2 61.0%  
Shareholders   56,727 31,796 178.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SANOFI INDIA  ABBOTT INDIA  PLETHICO PHARMA  CIPLA  TORRENT PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Aug 17, 2017 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS